Copyright
©The Author(s) 2021.
World J Gastroenterol. Nov 7, 2021; 27(41): 7041-7064
Published online Nov 7, 2021. doi: 10.3748/wjg.v27.i41.7041
Published online Nov 7, 2021. doi: 10.3748/wjg.v27.i41.7041
Table 1 Registered clinical trials on ClinicalTrials.gov (as accessed on April 2021) focused on fecal microbiota transplantation for the replacement of obesogenic microbial communities. Search terms included “gut microbiota”, “obesity” and “fecal microbiota transplantation”
Rank | Title | Status | Results | Condition | Intervention | Location | URL |
1 | Fecal Microbiota Transplantation for the Treatment of Obesity | Completed | Available | Obesity | FMT vs placebo | United States | https://ClinicalTrials.gov/show/NCT02741518 |
2 | Faecal Microbiota Transplantation in Obesity | Recruiting | Not available | Obesity | FMT vs placebo | Finland | https://ClinicalTrials.gov/show/NCT03391817 |
3 | Randomized Controlled Trial of Fecal Microbiota Transplantation in Severe Obesity | Enrolling by invitation | Not available | Obesity | FMT vs placebo | Norway | https://ClinicalTrials.gov/show/NCT03273855 |
4 | Fecal Microbiota Transplant (FMT) to Induce Weight Loss in Obese Subjects | Active, not recruiting | Not available | Obesity | FMT and mucosal microbiota assessment | China | https://ClinicalTrials.gov/show/NCT03789461 |
5 | FMT and Fiber in Patients With Metabolic Syndrome | Completed | Not available | Obesity, Metabolic Syndrome | FMT and dietary supplement with fiber (cellulose) vs placebo | Canada | https://ClinicalTrials.gov/show/NCT03727321 |
6 | Assessment of the Health Improvement of Obese Patients After Fecal Microbiota Transplantation (FMT) | Completed | Not available | Obesity, Type 1 and 2 Diabetes | FMT | Russian Federation | https://ClinicalTrials.gov/show/NCT04579263 |
7 | Fecal Microbiota Transplantation for Diabetes Mellitus Type II in Obese Patients | Unknown status | Not available | T2DM, Obesity | FMT and dietary intervention (high-fat low-fiber diet, sham diet or low-fat high-fiber diet) | Israel | https://ClinicalTrials.gov/show/NCT02346669 |
8 | Fecal Microbial Transplantation and Fiber Supplementation in Participants With Obesity and Metabolic Syndrome | Active, not recruiting | Not available | Obesity, Metabolic Syndrome | FMT and dietary supplement with fiber (cellulose) or FMT only vs placebo | Canada | https://ClinicalTrials.gov/show/NCT03477916 |
9 | Randomised Placebo-controlled Study of FMT to Impact Body Weight and Glycemic Control in Obese Subjects With T2DM | Active, not recruiting | Not available | T2DM, Obesity | FMT and lifestyle modification program or FMT only vs placebo | China | https://ClinicalTrials.gov/show/NCT03127696 |
10 | Fecal Microbiota Transplant for Improvement of Metabolism | Completed | Available | Obesity | FMT vs placebo | United States | https://ClinicalTrials.gov/show/NCT02530385 |
11 | The Role of Microbiome in Recurrent Obesity | Not yet recruiting | Not available | Obesity | FMT vs placebo | Israel | https://ClinicalTrials.gov/show/NCT04697550 |
12 | Effects of Fecal Microbiota Transplantation on Weight in Obese Patients With Non-alcoholic Fatty Liver Disease | Recruiting | Not available | NAFLD | FMT, dietary intervention and physical activity vs placebo | India | https://ClinicalTrials.gov/show/NCT04594954 |
13 | Proposal to Examine the Effect of Fecal Transplantation on Obesity | Unknown status | Not available | Obesity | FMT vs placebo | Israel | https://ClinicalTrials.gov/show/NCT02336789 |
14 | Safety and Efficacy of Fecal Microbiota Transplantation | Recruiting | Not available | IBD, IBS, Obesity, Metabolic Syndrome, Infections, Others | FMT | China | https://ClinicalTrials.gov/show/NCT04014413 |
15 | Transplantation of Microbes for Treatment of Metabolic Syndrome & NAFLD | Completed | Not available | Type 1 and 2 Diabetes, NAFLD, Obesity | FMT | Canada | https://ClinicalTrials.gov/show/NCT02496390 |
- Citation: Barone M, D'Amico F, Fabbrini M, Rampelli S, Brigidi P, Turroni S. Over-feeding the gut microbiome: A scoping review on health implications and therapeutic perspectives. World J Gastroenterol 2021; 27(41): 7041-7064
- URL: https://www.wjgnet.com/1007-9327/full/v27/i41/7041.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i41.7041